Gene therapy hope for kids and adults with rare Blindness-Causing mutation
NCT ID NCT07063030
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a gene therapy called LX107 for people with a rare inherited eye disease caused by mutations in the AIPL1 gene. The treatment is given as an injection under the retina to try to improve vision and slow disease progression. The study will include 13 adults and children aged 4 and older, and will focus on safety and whether the therapy helps with mobility in different lighting conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINAL DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••